​

Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)

OwnershipFinancialsChart

Previous Close

$1.16

52W Range

$0.80 - $3.08

50D Avg

$1.06

200D Avg

$1.49

Market Cap

$52.18M

Avg Vol (3M)

$20.16K

Beta

-1.16

Div Yield

-

ANEB Company Profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

May 07, 2021

Website

ANEB Performance

ANEB Financial Summary

Jun 24Jun 23Jun 22
Revenue---
Operating Income$-8.31M$-11.78M$-6.83M
Net Income$-8.20M$-11.73M$-6.81M
EBITDA$-8.31M$-11.78M$-6.83M
Basic EPS$-0.32$-0.47$-0.29
Diluted EPS$-0.32$-0.47$-0.29

Fiscal year ends in Jun 24 | Currency in USD

Peer Comparison

TickerCompany
MLYSMineralys Therapeutics, Inc.
MOLNMolecular Partners AG
ADAGAdagene Inc.
PMVPPMV Pharmaceuticals, Inc.
ANABAnaptysBio, Inc.
OPTOpthea Limited
ACRVAcrivon Therapeutics, Inc. Common Stock
AVTEAerovate Therapeutics, Inc.
ANTXAN2 Therapeutics, Inc.